A Tailored, Web-based Program (COMPASS) to Improve Exercise and Dietary Changes in Stage I-III Pancreatic Cancer Patients Receiving Neoadjuvant Chemotherapy
2026年6月12日 更新者：Kerri Winters、OHSU Knight Cancer Institute
Community for Physical Activity and Supportive Nutrition Strategies (COMPASS)
This clinical trial studies whether a tailored, web-based program (web portal), Community for Physical Activity and Supportive Nutrition Strategies (COMPASS), can be used to improve exercise and dietary changes in patients with stage I-III pancreatic cancer who are receiving chemotherapy before surgery (neoadjuvant).
Pancreatic cancer is a rare and understudied cancer, particularly in the area of promoting a healthy lifestyle to preserve physical and mental well-being during a long and difficult treatment regimen.
Since pancreatic cancer is rare, programs have limited resources available to reach the patients who could benefit from programs aimed at promoting exercise and a healthy diet.
The COMPASS web-portal is easily accessed by the patient via a computer, tablet, or phone.
It is tailored to the unique needs of pancreatic cancer patients and provides exercise and diet recommendations along with behavioral support as they undergo the long process of cancer therapy.
This may be a more effective way to reach and engage with the patient, which may improve exercise and dietary changes in stage I-III pancreatic cancer patients receiving neoadjuvant chemotherapy.
研究概览
地位
招聘中
详细说明
PRIMARY OBJECTIVE:
I. Acceptability of the COMPASS web portal will be assessed through accrual, study retention, end-of-study focus groups, and exit surveys, while feasibility will be measured by adherence to prescribed recommendations, frequency of portal visits, and aggregate web portal usage data.
SECONDARY OBJECTIVE:
I. To evaluate the preliminary effectiveness of COMPASS on exercise and diet habits, self-efficacy for behavior change, stages of change for exercise, changes in physical and mental well-being, and treatment tolerance (treatment-related symptoms, side effects, # of dose reductions) at baseline, 3 months and post chemotherapy.
TERTIARY OBJECTIVE:
I. To compare outcomes between participants assigned to a single health coaching session or monthly coaching sessions.
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP 1: Patients receive access to COMPASS portal, a tailored exercise intervention which may consist of strength, aerobic, balance, and flexibility exercises, and tailored diet recommendations for the duration of neoadjuvant chemotherapy. Patients also attend two review sessions to discuss the tailored exercise intervention and dietary recommendations and may optionally receive motivational and support text messages three times a week (TIW) on study.
GROUP 2: Patients receive access to COMPASS portal, a tailored exercise intervention which may consist of strength, aerobic, balance, and flexibility exercises, and tailored diet recommendations for the duration of neoadjuvant chemotherapy. Patients also attend two review sessions to discuss the tailored exercise intervention and dietary recommendations and receive a coaching call once a month on study. Additionally, patients may optionally receive motivational and support text messages TIW on study.
研究类型
介入性
注册 (估计的)
30
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。
学习地点
-
-
Oregon
-
Portland、Oregon、美国、97239
- 招聘中
- OHSU Knight Cancer Institute
-
接触：
- Kerri Winters-Stone
- 电话号码：503-494-0813
- 邮箱：wintersk@ohsu.edu
-
首席研究员：
- Kerri Winters-Stone
-
-
参与标准
研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
不
描述
Inclusion Criteria:
Age 18 years or older on date of enrollment
- Confirmed by review of the date of birth as documented in the electronic medical record (EMR) and subsequently recorded in a case report form (CRF)
Diagnosed with stage I-III pancreatic cancer
- Confirmed by EMR review. In cases where the EMR is unclear, their physician will be contacted and asked to confirm
Scheduled to receive neoadjuvant chemotherapy at Oregon Health & Science University (OHSU)
- Confirmed by EMR review. In cases where the EMR is unclear, their physician will be contacted and asked to confirm
Willing to adhere to the study protocol
- Confirmed verbally with the participant and response documented in the Participant Tracking database
Exclusion Criteria:
Cognitive difficulties that preclude answering the survey questions, participating in the intervention, or giving informed consent
- In the event of a suspected undeclared cognitive impairment, it will be confirmed by physician clearance or professional opinion of the Principal Investigators, Dr. Kerri Winters-Stone and/or Dr. Jackilen Shannon
A medical condition, movement or neurological disorder, or medication use that contraindicates participation in light intensity exercise
- Confirmed by a combination of reviewing the EMR, and self-report during the initial screening call. If in the professional opinion of the Principal Investigator, Dr. Kerri Winters-Stone or Dr. Jackilen Shannon, contraindications other than those identified by the patient or physician are present, she may consider the participant ineligible
Not fluent in English and therefore incapable of answer survey questions, reading the intervention web portal, and providing informed consent in English
- Confirmed verbally with the participant and response documented in the Participant Tracking database
学习计划
本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。
研究是如何设计的？
设计细节
- 主要用途：支持治疗
- 分配：随机化
- 介入模型：并行分配
- 屏蔽：无（打开标签）
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：Group 1 (COMPASS + brief coaching support)
Participants receive access to COMPASS portal, a tailored exercise intervention which may consist of strength, aerobic, balance, and flexibility exercises, and tailored diet recommendations for the duration of neoadjuvant chemotherapy.
Participants also receive an initial coaching call to discuss the tailored exercise intervention and dietary recommendations and may optionally receive motivational and support text messages TIW on study.
|
Web-based lifestyle program that provides tailored nutrition and physical activity recommendations and web-based support strategies including text messages, electronic trackers, and coaching
|
|
实验性的：Group 2 (COMPASS + enhanced coaching support)
Participants receive the same intervention as Group 1, but receive additional monthly coaching support
|
Web-based lifestyle program that provides tailored nutrition and physical activity recommendations and web-based support strategies including text messages, electronic trackers, and coaching
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Accrual (Acceptability)
大体时间：Up to 12 months
|
Accrual will be measured by the number of eligible patients who enroll in the study divided by the total number approached for recruitment.
Successful accrual will be defined as recruiting 30 pancreatic cancer patients
|
Up to 12 months
|
|
Study retention (Acceptability)
大体时间：Up to 12 months
|
Measured by the number of participants who enroll and complete the study intervention during their neoadjuvant chemotherapy treatment.
Successful retention will be if 80% (24) participants complete the study's intervention while in neoadjuvant chemotherapy.
|
Up to 12 months
|
|
Listening session
大体时间：At completion of neoadjuvant chemotherapy (average of 6 months)
|
A minimum of 2 and maximum of 4 virtual listening sessions, at least one of men and one of women will be conducted.
Each group will consist of 8-10 individuals and will explore questions of ease of use, whether they felt the portal was engaging and effectively encouraged positive behaviors.
Information will also be sought about how the portal may be improved.
|
At completion of neoadjuvant chemotherapy (average of 6 months)
|
|
Exit survey
大体时间：At completion of neoadjuvant chemotherapy (average of 6 months)
|
This survey will assess which parts of the web portal and intervention participants felt were most useful.
The survey includes questions about each component of the web portal and intervention, with responses ranging from "Strongly Disagree" to "Strongly Agree," as well as open-ended questions that allow participants to provide additional thoughts or comments about the web portal.
|
At completion of neoadjuvant chemotherapy (average of 6 months)
|
|
Study intervention adherence (Feasibility)
大体时间：Up to 12 months
|
Adherence will be defined as the proportion of participants who achieve at least one prescribed weekly exercise goal or nutrition recommendation during ≥80% of the weeks of their neoadjuvant chemotherapy period.
Values range from 0% to 100%, with higher percentages indicating greater adherence to the study intervention.
|
Up to 12 months
|
|
Web portal visit frequency (Feasibility)
大体时间：Up to 12 months
|
Will be measured by the number of times participants logged into the web portal during the intervention period.
|
Up to 12 months
|
|
Web portal aggregate activity (Feasibility)
大体时间：Up to 12 months
|
The number of clicks on specific web portal components, most frequently visited web pages, average time spent on the web portal and on different sections, time spent logging information or syncing Fitbit data
|
Up to 12 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in self-report physical activity behavior
大体时间：At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
Will be assessed using the Community Health Activities Model Program physical activity survey as total energy expended in moderate to vigorous physical activity per week (kcal/week)
|
At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
|
Change in dietary behavior
大体时间：At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
Will be assessed using the Diet Questionnaire for Oncology Participants.
This survey assesses the frequency of consumption of specific foods or food groups (e.g., bread, cereal, milk, fruit juice) and how much of each food they typically eat per week.
|
At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
|
Change in objectively measured physical activity (kcal/week)
大体时间：At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
Physical activity will be measured using a Fitbit device for energy expenditure (kcal/week)
|
At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
|
Change in objectively measured physical activity (daily step count)
大体时间：At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
Physical activity will be measured using a Fitbit activity monitor and reported as average daily step count.
Daily step count represents the total number of steps accumulated during a day.
Possible values range from 0 steps to no defined upper limit.
Higher values (average daily steps) indicate greater physical activity.
|
At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
|
Change in Self-efficacy for Exercise score
大体时间：At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
Will be measured using a 6-item measure of Self-efficacy for Exercise.
Summed scores range from 6-30, and higher scores indicate higher self-efficacy
|
At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
|
Change in stages of change for exercise
大体时间：At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
Will be assessed using the Physical Activity Stage Assessment (PASA) measure.
Participants select one of five statements that best describes their current exercise behavior and readiness to engage in regular physical activity.
Values range from 1 to 5, with higher values indicating greater engagement in and maintenance of regular exercise.
|
At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
|
Healthy Eating and Weight Self-Efficacy
大体时间：At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
The Healthy Eating and Weight Self-Efficacy (HEWSE) questionnaire assesses participants' self-efficacy by asking them to rate their confidence in performing various tasks on a 1-5 Likert scale.
A score of 1 indicates strong disagreement with their ability to accomplish the task, while a score of 5 indicates strong agreement.
Higher scores indicate greater self-efficacy for healthy eating and weight management behaviors.
|
At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
|
Change in self-report physical functioning, quality of life, and cancer related symptoms
大体时间：At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
Will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30).
This outcome will assess overall quality of life and cancer-related symptoms.
Scores range from 0 to 100.
For the global health status and functional scales, higher scores indicate better quality of life and functioning.
For symptom scales, higher scores indicate greater symptom burden and worse outcomes.
|
At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
|
Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Symptom Measures
大体时间：At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
Will be assessed using the Participant-Reported Outcomes Measurement Information System (PROMIS) measures for Sleep Disturbance, Depression, Anxiety, and Fatigue.
Participants respond to 8-13 questions regarding their symptoms, with responses ranging from "Not at all" to "Very much."
Scores are converted to standardized T-scores, with higher scores indicating greater symptom severity and worse outcomes.
|
At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
|
Change in cognitive function
大体时间：At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
Will be assessed using the Participant-Reported Outcomes Measurement Information System Cognitive Function (PROMIS-CF) survey.
This 32-item questionnaire assesses perceived difficulties with memory, cognitive processing, and the impact of cognitive problems on daily and social activities.
Scores range from 0 to 100, with higher scores indicating better cognitive function and fewer perceived cognitive difficulties.
|
At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
|
Change in neuropathy
大体时间：At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
Will be assessed using the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity 4 (FACT-GOG-NXT-4).
This 4-item survey captures symptoms of peripheral neuropathy, including sensory, motor, and auditory problems and cold sensitivity.
Higher scores indicate more symptoms
|
At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
|
Change in pain
大体时间：At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
Will be assessed using the Participant-Reported Outcomes Measurement Information System (PROMIS) Pain Intensity and Pain Interference measures.
The Pain Intensity measure assesses the severity of pain, while the Pain Interference measure assesses the extent to which pain affects daily activities, social activities, and overall functioning.
Scores range from 0 to 100, with higher scores indicating greater pain severity and greater interference of pain with daily functioning, representing worse outcomes.
|
At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
|
Change in treatment dosing
大体时间：At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
These data will be available via the electronic health record and may be extracted to explore the impact of COMPASS on clinical outcomes including grade 3+ toxicities, dose delays and dose reductions.
|
At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
|
Incidence of adverse events
大体时间：At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
Tolerance and safety will be assessed by adverse event reporting administered monthly by a survey administered by the web portal.
Adverse events will be classified as related, possibly related, or not related to the intervention and graded as mild, moderate or severe.
|
At baseline, 3 months, and the completion of neoadjuvant chemotherapy up to 12 months
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员：Kerri Winters-Stone、OHSU Knight Cancer Institute
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2026年4月15日
初级完成 (估计的)
2027年1月31日
研究完成 (估计的)
2027年6月30日
研究注册日期
首次提交
2026年4月28日
首先提交符合 QC 标准的
2026年6月12日
首次发布 (实际的)
2026年6月16日
研究记录更新
最后更新发布 (实际的)
2026年6月16日
上次提交的符合 QC 标准的更新
2026年6月12日
最后验证
2026年6月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.